Eupraxia Pharmaceuticals Inc. (EPRX) Key Metrics
EPRX valuation today
Trailing 12 months · as of October 18, 2026- Market cap
- $437.4M
- Enterprise value
- $430.7M
- P/E (TTM)
- —
- Forward P/E
- —
- PEG ratio
- —
- Price / sales
- —
- Price / book
- 5.0
- EV / EBITDA
- —
- Dividend yield
- —
- Beta
- 1.22
EPRX key metrics, 2017–2025
Fiscal year ended December 31, 2025 · U.S. dollarsEPRX valuation Price multiples at each fiscal year-end price.
EPRX returns How much profit the business earns on the capital it uses.
EPRX per-share figures Results divided by the shares outstanding at year-end.
EPRX financial health Debt, liquidity and how easily interest is covered.
EPRX valuation history
EPRX returns on capital
Net income (ROE, ROA) or after-tax operating income (ROIC) divided by the average of the opening and closing balance.
EPRX debt vs cash
Debt includes short- and long-term borrowings and, where reported, lease liabilities.
EPRX price vs earnings per share
EPRX key metrics
2017–2025| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | |
|---|---|---|---|---|---|---|---|---|---|
| Valuation | |||||||||
| Market capitalization | $301.7M | $107.6M | — | — | — | — | — | — | — |
| Enterprise value | $221.3M | $74.5M | — | — | — | — | — | — | — |
| Price / book | 3.7 | 3.2 | — | — | — | — | — | — | — |
| Earnings yield | −12.8% | −23.7% | — | — | — | — | — | — | — |
| Free cash flow yield | −9.8% | −28.0% | — | — | — | — | — | — | — |
| Share price at fiscal year-end | $7.55 | $3.17 | — | — | — | — | — | — | — |
| Per share | |||||||||
| Revenue per share | $0.00 | $0.00 | $0.00 | $0.00 | — | — | — | — | — |
| Earnings per share | −$0.97 | −$0.75 | −$0.88 | −$0.96 | — | — | — | — | — |
| Operating cash flow per share | −$0.73 | −$0.88 | −$0.65 | −$0.75 | — | — | — | — | — |
| Free cash flow per share | −$0.74 | −$0.89 | −$0.65 | −$0.76 | — | — | — | — | — |
| Cash per share | $2.02 | $0.98 | $0.60 | $1.28 | — | — | — | — | — |
| Book value per share | $2.05 | $0.98 | $0.07 | $0.55 | — | — | — | — | — |
| Tangible book value per share | $2.05 | $0.98 | $0.07 | $0.55 | — | — | — | — | — |
| Capex per share | $0.01 | $0.00 | $0.00 | $0.01 | — | — | — | — | — |
| Debt per share | $0.00 | $0.00 | $0.33 | $0.63 | — | — | — | — | — |
| Shares outstanding | 40.0M | 33.9M | 24.1M | 19.3M | — | — | — | — | — |
| Change in shares outstanding | +17.8% | +40.5% | +25.2% | — | — | — | — | — | — |
| Returns & profitability | |||||||||
| Return on equity (ROE) | −66.8% | −145.4% | −348.0% | −121.3% | — | — | — | — | −73.3% |
| Return on invested capital (ROIC) | — | — | — | — | — | — | — | — | −200.4% |
| Return on assets (ROA) | −63.7% | −101.6% | −103.3% | −64.7% | −146.6% | −169.1% | −238.0% | −298.5% | −73.9% |
| Return on tangible assets | −44.8% | −73.0% | −139.3% | −71.4% | −76.7% | −275.6% | −224.4% | −453.4% | −73.9% |
| Financial health | |||||||||
| Total debt | $154,362 | $71,859 | $7.9M | $12.2M | $10.0M | $12.8M | $11.9M | $3.8M | $12,474 |
| Cash & short-term investments | $80.6M | $33.1M | $14.6M | $24.7M | $29.9M | $150,126 | $1.2M | $823,481 | $4.0M |
| Net debt | −$80.4M | −$33.0M | −$6.7M | −$12.6M | −$19.9M | $12.6M | $10.8M | $3.0M | −$4.0M |
| Debt / equity | 0.00 | 0.00 | 4.72 | 1.15 | 0.50 | — | — | — | 0.00 |
| Debt / assets | 0.00 | 0.00 | 0.52 | 0.47 | 0.32 | 8.78 | 3.63 | 1.30 | 0.00 |
| Current ratio | 15.12 | 11.10 | 1.02 | 6.08 | 13.49 | 0.05 | 0.13 | 0.17 | 7.53 |
| Quick ratio | 15.12 | 11.10 | 1.02 | 6.08 | 13.49 | 0.05 | 0.13 | 0.17 | 7.53 |
| Interest coverage | — | -44.7 | -23.8 | -17.9 | -15.8 | -1.3 | -4.7 | -84.6 | -93.3 |
| Working capital | $79.5M | $31.3M | $323,137 | $21.0M | $28.3M | −$21.4M | −$18.0M | −$11.9M | $4.8M |
| Invested capital | $1.6M | $375,368 | −$5.0M | −$2.0M | $41,990 | −$8.6M | −$6.9M | −$8.1M | $1.9M |
| Tangible asset value | $80.4M | $31.8M | $671,855 | $9.8M | $19.1M | −$21.7M | −$18.1M | −$11.4M | $5.2M |
| Net current asset value | $79.4M | $31.3M | $323,137 | $9.0M | $18.5M | −$22.0M | −$18.8M | −$11.9M | $4.8M |
| Graham net-net per share | $1.89 | $0.89 | $0.00 | $0.45 | — | — | — | — | — |
| Capital allocation | |||||||||
| Capex / depreciation | 2.52 | 0.61 | 0.47 | 1.59 | 3.87 | 0.00 | 0.05 | 1.13 | 3.69 |
| Efficiency | |||||||||
| Days of inventory on hand | — | — | 0.0 | 0.0 | 0.0 | 0.0 | — | — | — |
| Receivables turnover | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Inventory turnover | — | — | 104,955.50 | 128,848.67 | 112,376.00 | 117,072.00 | — | — | — |
| Asset turnover | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Average receivables | $451,549 | $186,194 | $116,616 | $261,350 | $459,837 | $759,430 | $1.3M | $1.4M | $1.3M |
| Average inventory | — | — | $2 | $2 | $1 | $1 | — | — | — |
| Intangibles / total assets | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% |
Computed from EPRX's annual financial statements (latest annual report filed March 13, 2026) and the closing share price on each fiscal year-end, adjusted for stock splits. Figures in U.S. dollars; data from EODHD. Averages use the opening and closing balance of each year.
EPRX valuation and financial ratios
Eupraxia Pharmaceuticals earned a return on equity of −66.8% in fiscal 2025. It ended the year with $0.2 million of debt and $80.6 million in cash and short-term investments, a net cash position of $80.4 million.
See the EPRX income statement, the EPRX chart for price history, or the EPRX stock overview for the latest quote and news.
EPRX key metrics FAQ
What is Eupraxia Pharmaceuticals's return on equity?
Eupraxia Pharmaceuticals's return on equity (ROE) was −66.8% in fiscal 2025: net income of -$38.6 million on average shareholders' equity of $57.7 million.
How much debt does Eupraxia Pharmaceuticals have?
Eupraxia Pharmaceuticals had total debt of $0.2 million at the end of fiscal 2025, a debt-to-equity ratio of 0.00 and more cash than debt.
What is Eupraxia Pharmaceuticals's free cash flow yield?
Eupraxia Pharmaceuticals generated -$29.6 million of free cash flow in fiscal 2025, a free cash flow yield of −9.8% on its market value at year-end ($301.7 million).
What is Eupraxia Pharmaceuticals's current ratio?
Eupraxia Pharmaceuticals's current ratio was 15.12 at the end of fiscal 2025: current assets were 15.12 times current liabilities.